RNS Number : 9123B
Haleon PLC
27 April 2026
Haleon plc: Aggregated information - transactions in own shares
27 April 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 8,444,107 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026.
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Aquis
Date of purchase:
20 April 2026
Number of Shares purchased:
821,869
367,453
507,955
-
Highest price paid per Share (p):
357.1000
357.0000
357.0000
-
Lowest price paid per Share (p):
352.7000
352.7000
352.7000
-
Volume weighted average price paid per Share (p):
355.6853
355.6923
355.7028
-
Date of purchase:
21 April 2026
Number of Shares purchased:
1,166,530
588,755
744,522
-
Highest price paid per Share (p):
356.8000
356.8000
356.8000
-
Lowest price paid per Share (p):
351.3000
351.3000
351.3000
-
Volume weighted average price paid per Share (p):
353.4925
353.2870
353.4540
-
Date of purchase:
22 April 2026
Number of Shares purchased:
1,704,866
979,361
797,024
-
Highest price paid per Share (p):
347.3000
347.3000
347.3000
-
Lowest price paid per Share (p):
342.7000
342.7000
342.7000
-
Volume weighted average price paid per Share (p):
345.6215
345.6369
345.6370
-
Date of purchase:
23 April 2026
Number of Shares purchased:
213,670
112,840
164,286
-
Highest price paid per Share (p):
351.4000
351.3000
351.3000
-
Lowest price paid per Share (p):
344.8000
344.8000
344.3000
-
Volume weighted average price paid per Share (p):
348.5780
348.5651
348.1893
-
Date of purchase:
24 April 2026
Number of Shares purchased:
111,010
73,582
90,384
-
Highest price paid per Share (p):
356.1000
356.1000
355.4000
-
Lowest price paid per Share (p):
350.5000
350.4000
350.4000
-
Volume weighted average price paid per Share (p):
352.1838
352.3097
352.1778
-
Following the settlement of the above, the Company's registered share capital is 8,902,639,582 ordinary shares of £0.01 each, of which 12,281,053 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,890,358,529 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
http://www.rns-pdf.londonstockexchange.com/rns/9123B_1-2026-4-24.pdf
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
Enquiries
Investors
Media
Jo Russell
+44 7787 392441
ZoëBird
+44 7736 746167
Rakesh Patel
+44 7552 484646
Victoria Durman
+44 7894 505730
Email:investor-relations@haleon.com
Email:corporate.media@haleon.com
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
POSBLGDSRUDDGLS
